The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    The effect of kihito extract granules in people with Alzheimer’s disease

    The most prominent neurochemical change in patients with Alzheimer’s disease is a deficiency of choline acetyltransferase, the enzyme responsible for the synthesis of acetylcholine.

    Polygalae radix is thought to be a useful component of kami-untan-to because it increases the activity of choline acetyltransferase. This study evaluated this Japanese herbal (kampo) medicine in people with Alzheimer’s disease.

    First, the details.

    • 75 elderly people with senile dementia of the Alzheimer’s type were treated with one of the following:
    • Kihito extract granules (a commercially available Japanese herbal medicine containing P. radix)
    • No treatment
    • Goshajinkigan (a kampo medicine that served as a placebo).

    And, the results.

    • The group treated with kihito extract granules showed significant improvement in the Mini-Mental State Examination (MMSE).
    • The other groups showed no improvement.
    • No side effects were reported.

    The bottom line?
    MMSE measures of cognition (intellectual thought). And the FDA uses it as one of the criteria for approving drugs to treat Alzheimer’s disease. The survey is shown here.

    The results are useful because, in addition to being positive, they can be compared to FDA-approved drugs to treat Alzheimer’s dementia.

    10/15/07 21:48 JR

    Leave a Comment

    You must be logged in to post a comment.